Study guide
8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV
Key Takeaways Explain This Topic AI
Long-term oxygen therapy in COPD requires a PaO2 below 7.3 kPa, or below 8.0 kPa with secondary polycythaemia, peripheral oedema or pulmonary hypertension, measured twice when stable.
Non-invasive ventilation is indicated in acute exacerbation of COPD when pH is 7.25-7.35 with PaCO2 above 6.0 kPa persisting after controlled oxygen and medical therapy.
Only smoking cessation, long-term oxygen therapy in hypoxaemic patients and lung volume reduction surgery in selected patients improve mortality in COPD.
Last updated: September 2026
4. Chronic Obstructive Pulmonary Disease (COPD): GOLD Staging & Stable Management
COPD is characterized by persistent, progressive, non-fully reversible airflow limitation arising from a combination of small airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema). Cigarette smoking is the predominant etiology, causing chronic neutrophilic and macrophage-mediated inflammation with release of matrix metalloproteinases and neutrophil elastase.
Spirometric Confirmation & GOLD Staging
Diagnosis requires post-bronchodilator spirometry confirming airflow obstruction with FEV 1 / FVC < 0.70 \text{FEV}_1/\text{FVC} < 0.70 FEV 1 / FVC < 0.70 . The severity of airflow limitation is graded by post-bronchodilator FEV 1 \text{FEV}_1 FEV 1 percentage predicted:
GOLD 1 (Mild): FEV 1 ≥ 80 % \text{FEV}_1 \ge 80\% FEV 1 ≥ 80% predicted.
GOLD 2 (Moderate): 50 % ≤ FEV 1 < 80 % 50\% \le \text{FEV}_1 < 80\% 50% ≤ FEV 1 < 80% predicted.
GOLD 3 (Severe): 30 % ≤ FEV 1 < 50 % 30\% \le \text{FEV}_1 < 50\% 30% ≤ FEV 1 < 50% predicted.
GOLD 4 (Very Severe): FEV 1 < 30 % \text{FEV}_1 < 30\% FEV 1 < 30% predicted.
GOLD Refined Assessment Framework (Groups A, B, E)
The 2023/2024 GOLD guidelines consolidated high exacerbation risk into Group E:
Group A: 0–1 moderate exacerbations not requiring hospital admission; low symptom burden (mMRC dyspnoea score 0–1 or CAT score < 10 < 10 < 10 ). Treatment: Initial bronchodilator (SABA, LABA, or LAMA).
Group B: 0–1 moderate exacerbations; high symptom burden (mMRC ≥ 2 \ge 2 ≥ 2 or CAT ≥ 10 \ge 10 ≥ 10 ). Treatment: First-line dual long-acting bronchodilators ( LABA + LAMA combination, e.g., vilanterol/umeclidinium, formoterol/glycopyrronium, or olodaterol/tiotropium).
Group E (Exacerbation Risk): ≥ 2 \ge 2 ≥ 2 moderate exacerbations or ≥ 1 \ge 1 ≥ 1 exacerbation resulting in hospital admission. Treatment: First-line LABA + LAMA . If peripheral blood eosinophil count is ≥ 300 cells/ μ L \ge 300\text{ cells/}\mu\text{L} ≥ 300 cells/ μ L , initiate Triple Therapy (LABA + LAMA + ICS) immediately. In patients on LABA + LAMA who develop recurrent exacerbations with blood eosinophils ≥ 100 cells/ μ L \ge 100\text{ cells/}\mu\text{L} ≥ 100 cells/ μ L , escalate to triple therapy. (The landmark IMPACT and ETHOS trials demonstrated that triple therapy significantly reduces moderate-to-severe exacerbations and improves all-cause survival compared to LABA/LAMA in this group).
Non-Pharmacological Interventions
Smoking Cessation: The single most effective disease-modifying intervention. Normal rate of FEV 1 \text{FEV}_1 FEV 1 decline ( 25 – 30 mL/year 25\text{–}30\text{ mL/year} 25 – 30 mL/year ) accelerates to 60 – 90 mL/year 60\text{–}90\text{ mL/year} 60 – 90 mL/year in active smokers; cessation slows the decline back to age-related physiological rates.
Pulmonary Rehabilitation: Indicated for patients with an MRC dyspnoea score ≥ 3 \ge 3 ≥ 3 or following an acute hospital admission for AECOPD. A structured 6–12 week multidisciplinary exercise training and educational programme proven to improve exercise endurance, reduce breathlessness, and lower hospital readmission rates.
Long-Term Oxygen Therapy (LTOT):
Assessed only when the patient is clinically stable on maximal therapy for ≥ 5 \ge 5 ≥ 5 weeks post-exacerbation.
Absolute Criteria: Resting ambient air PaO 2 < 7.3 kPa \text{PaO}_2 < 7.3\text{ kPa} PaO 2 < 7.3 kPa ( < 55 mmHg < 55\text{ mmHg} < 55 mmHg ).
Relative Criteria: Resting PaO 2 \text{PaO}_2 PaO 2 between 7.3 and 8.0 kPa 7.3\text{ and } 8.0\text{ kPa} 7.3 and 8.0 kPa ( 55 – 60 mmHg 55\text{–}60\text{ mmHg} 55 – 60 mmHg ) in the presence of secondary polycythaemia (haematocrit ≥ 55 % \ge 55\% ≥ 55% ), clinical or echocardiographic evidence of pulmonary hypertension, peripheral oedema (cor pulmonale), or documented nocturnal hypoxaemia.
Must be utilized for ≥ 15 hours/day \ge 15\text{ hours/day} ≥ 15 hours/day (including sleep) to provide a statistically significant mortality benefit. Strictly prohibited in active smokers due to severe facial burn and domestic fire hazards.
5. Acute Exacerbations of COPD (AECOPD) & Non-Invasive Ventilation (NIV)
An acute exacerbation of COPD is characterized by acute worsening of respiratory symptoms (dyspnoea, cough, sputum volume, and purulence) beyond normal day-to-day variations, predominantly precipitated by respiratory viral or bacterial infections ( Haemophilus influenzae , Streptococcus pneumoniae , Moraxella catarrhalis , Pseudomonas aeruginosa ).
Controlled Oxygen Delivery: Avoiding Hypercapnic Coma
Patients with severe COPD have chronic ventilation-perfusion (V/Q) mismatching. Administering unregulated high-flow oxygen precipitates acute hypercapnia via three distinct pathophysiological mechanisms:
Reversal of Hypoxic Pulmonary Vasoconstriction: High alveolar oxygen causes vasodilation in poorly ventilated lung units, dramatically increasing physiological dead space ( V D / V T V_D/V_T V D / V T ). (This is the dominant mechanism, contributing > 70 % > 70\% > 70% of the rise in PaCO 2 \text{PaCO}_2 PaCO 2 ).
The Haldane Effect: Oxygenation of deoxygenated haemoglobin reduces its affinity for CO 2 \text{CO}_2 CO 2 , displacing CO 2 \text{CO}_2 CO 2 from carbamino compounds into plasma, raising dissolved blood PaCO 2 \text{PaCO}_2 PaCO 2 .
Blunting of Ventilatory Drive: Modest reduction in carotid body chemoreceptor stimulation.
Clinical Practice: Administer oxygen via a 24 % 24\% 24% or 28 % 28\% 28% Venturi mask (or nasal cannulae at 1 – 2 L/min 1\text{–}2\text{ L/min} 1 – 2 L/min ) strictly targeting an oxygen saturation of 88 – 92 % 88\text{–}92\% 88 – 92% . Repeat an arterial blood gas (ABG) within 30 to 60 minutes.
Pharmacotherapy of AECOPD
Bronchodilators: Nebulised salbutamol ( 2.5 – 5 mg 2.5\text{–}5\text{ mg} 2.5 – 5 mg ) and ipratropium bromide ( 500 μ g 500\ \mu\text{g} 500 μ g ) driven by compressed medical air (NOT cylinder oxygen; oxygen-driven nebulisers deliver 100 % FiO 2 100\%\ \text{FiO}_2 100% FiO 2 and induce fatal hypercapnia).
Corticosteroids: Oral prednisolone 30 mg 30\text{ mg} 30 mg once daily for 5 days (prolonged courses offer no additional benefit and increase adverse events).
Antibiotics: Indicated if the patient exhibits increased sputum purulence or requires mechanical ventilation. First-line oral choices: amoxicillin ( 500 mg 500\text{ mg} 500 mg tds), doxycycline ( 200 mg 200\text{ mg} 200 mg stat then 100 mg 100\text{ mg} 100 mg od), or clarithromycin ( 500 mg 500\text{ mg} 500 mg bd) for 5 days.
Non-Invasive Ventilation (NIV / BiPAP)
Primary Indication: Acute hypercapnic respiratory failure (Type 2) secondary to COPD exacerbation with persistent respiratory acidosis (defined as pH 7.25 – 7.35 \text{pH } 7.25\text{–}7.35 pH 7.25 – 7.35 and PaCO 2 > 6.0 kPa \text{PaCO}_2 > 6.0\text{ kPa} PaCO 2 > 6.0 kPa ) persisting after 1 hour of optimal medical management and controlled oxygen therapy.
Physiological Action: Delivers Inspiratory Positive Airway Pressure (IPAP, typically starting at 10 – 12 cmH 2 O 10\text{–}12\text{ cmH}_2\text{O} 10 – 12 cmH 2 O and titrated to 16 – 20 cmH 2 O 16\text{–}20\text{ cmH}_2\text{O} 16 – 20 cmH 2 O ) to assist diaphragmatic work and augment tidal volume, reducing PaCO 2 \text{PaCO}_2 PaCO 2 . Expiratory Positive Airway Pressure (EPAP, typically 4 – 5 cmH 2 O 4\text{–}5\text{ cmH}_2\text{O} 4 – 5 cmH 2 O ) prevents small airway collapse and overcomes intrinsic PEEP (PEEPi).
Absolute/Relative Contraindications: Respiratory arrest, Glasgow Coma Scale < 8 < 8 < 8 (unless hypercapnic coma where an immediate trial under close supervision is warranted), facial burns/trauma, bowel obstruction, severe uncontrolled vomiting, undrained pneumothorax, or severe hemodynamic instability requiring vasopressors.
6. BTS/SIGN Asthma Management vs. GOLD COPD Staging & Regimens
Feature Asthma (BTS/SIGN / GINA) Chronic Obstructive Pulmonary Disease (GOLD)
Primary Pathology Th2/eosinophilic airway inflammation; mast cells, CD4+ T cells Neutrophils, CD8+ T lymphocytes, alveolar macrophages; alveolar wall destruction
Airflow Limitation Reversible, episodic, highly variable Largely fixed, progressive, non-fully reversible
Diagnostic Hallmark FeNO ≥ 40 ppb \text{FeNO} \ge 40\text{ ppb} FeNO ≥ 40 ppb ; BDR ≥ 12 % \ge 12\% ≥ 12% and ≥ 200 mL \ge 200\text{ mL} ≥ 200 mL ; PEF variability > 20 % > 20\% > 20% Post-bronchodilator FEV 1 / FVC < 0.70 \text{FEV}_1/\text{FVC} < 0.70 FEV 1 / FVC < 0.70
First-Line Maintenance Inhaled Corticosteroid (ICS) + formoterol (MART) or regular low-dose ICS Long-acting bronchodilator: LABA + LAMA combination
Role of ICS Essential cornerstone from Step 1/2; prevents fatal exacerbations Add-on therapy (Triple Therapy) reserved for blood eosinophils ≥ 300 cells/ μ L \ge 300\text{ cells/}\mu\text{L} ≥ 300 cells/ μ L or frequent exacerbators
Exacerbation Oxygen Target 94 – 98 % 94\text{–}98\% 94 – 98% via high-flow reservoir mask 88 – 92 % 88\text{–}92\% 88 – 92% via 24 – 28 % 24\text{–}28\% 24 – 28% Venturi mask (prevent hypercapnia)
Ventilatory Support in Acute Crisis Invasive endotracheal intubation (NIV rarely indicated due to high failure rates) Non-Invasive Ventilation (NIV / BiPAP) first-line for pH 7.25 – 7.35 \text{pH } 7.25\text{–}7.35 pH 7.25 – 7.35 and PaCO 2 > 6.0 kPa \text{PaCO}_2 > 6.0\text{ kPa} PaCO 2 > 6.0 kPa